Search results
Google site results
Loading...
Wiki results
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==14 KB (1,944 words) - 14:29, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==15 KB (2,084 words) - 14:18, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,705 words) - 12:38, 3 November 2023
- ...>Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579</ref> ...ton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 8;26(3):319-30.</ref>3 KB (421 words) - 11:29, 22 August 2016
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,329 words) - 15:49, 20 December 2023
- ...www.ncbi.nlm.nih.gov/pubmed/?term=30377088 30377088]] with permission from Cancer Genetics. ''See [[MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alteration ==General Disease Overview / Description of Cancer Category==4 KB (539 words) - 12:29, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==11 KB (1,525 words) - 16:28, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,721 words) - 13:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,369 words) - 16:36, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,134 words) - 12:35, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,613 words) - 12:43, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,446 words) - 12:28, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,880 words) - 12:33, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==15 KB (2,153 words) - 14:35, 13 December 2023
- ...iginal page can be found at [[HAEM4:B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1]]. ==Cancer Category / Type==17 KB (2,425 words) - 14:21, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==15 KB (2,169 words) - 16:29, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,652 words) - 13:53, 3 November 2023
- UT MD Anderson Cancer Center ==Cancer Category/Type==12 KB (1,654 words) - 12:27, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,577 words) - 12:39, 3 November 2023
- ==Cancer Category/Type== *[[Mature T- and NK-cell Neoplasms|Mature T- and NK-cell Neoplasm]]9 KB (1,310 words) - 12:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,919 words) - 16:27, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,265 words) - 12:54, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==11 KB (1,569 words) - 12:35, 3 November 2023
- ...stic large cell lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 12/13/2023, <nowiki>https://ccga.io/inde ...ccur.<ref>Karikari, I.O.; Thomas, K.K.; Lagoo, A.; Cummings, T.J.; George, T.M. Primary Cerebral ALK-1-Positive Anaplastic Large Cell Lymphoma in a Chil10 KB (1,484 words) - 22:04, 27 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,603 words) - 12:27, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,020 words) - 14:30, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,485 words) - 16:22, 4 December 2023
- ==Cancer Category / Type== Mature T-cell neoplasm / Cutaneous T-cell lymphoma19 KB (2,695 words) - 14:39, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==14 KB (1,883 words) - 14:30, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,607 words) - 14:29, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,586 words) - 12:34, 3 November 2023
- {{DISPLAYTITLE:Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1}} ==Cancer Category/Type==12 KB (1,667 words) - 16:30, 4 December 2023
- UT MD Anderson Cancer Center ==Cancer Category/Type==12 KB (1,692 words) - 13:40, 3 November 2023
- ==Cancer Category/Type== Non-small cell lung cancer (NSCLC)12 KB (1,650 words) - 14:21, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,617 words) - 16:33, 4 December 2023
- {{DISPLAYTITLE:Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract}} ==Cancer Category/Type==10 KB (1,358 words) - 16:40, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==11 KB (1,602 words) - 13:47, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==16 KB (2,198 words) - 12:37, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==16 KB (2,259 words) - 14:18, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,642 words) - 13:40, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,304 words) - 16:43, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==17 KB (2,355 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,368 words) - 13:43, 3 November 2023
- ==Cancer Category / Type== Breast cancer / Fibroepithelial Tumors of the Breast16 KB (2,255 words) - 13:27, 29 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,231 words) - 13:48, 3 November 2023
- ==Cancer Category/Type== T- Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL)12 KB (1,609 words) - 12:57, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,626 words) - 16:28, 4 December 2023
- ==Cancer Category/Type== * [[Mature T- and NK-cell Neoplasms|Mature T- and NK-cell lymphoma]]10 KB (1,340 words) - 12:49, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==14 KB (1,944 words) - 14:27, 13 December 2023
- HAEM4Backup:Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM[[File:t(3;3)(q21;q26.2).png|t(3;3)(q21;q26.2)]] ==Cancer Category/Type==17 KB (2,499 words) - 12:32, 3 November 2023
- ==Cancer Category/Type== Colorectal cancer13 KB (1,790 words) - 18:29, 5 January 2019
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==16 KB (2,262 words) - 14:40, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,044 words) - 10:09, 27 February 2024
- {{DISPLAYTITLE:T-ALL/MEF2C}} ==Cancer Category/Type==12 KB (1,643 words) - 14:00, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,866 words) - 11:58, 13 April 2020
- ...he original page can be found at [[HAEM4:Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214]]. [[File:T(6;9)(p23;q34).png]]19 KB (2,611 words) - 14:17, 13 December 2023
- ...al page can be found at [[HAEM4:Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged]]. ==Cancer Category / Type==19 KB (2,659 words) - 14:32, 13 December 2023
- {{DISPLAYTITLE:Monomorphic Epitheliotropic Intestinal T-cell Lymphoma}} ==Cancer Category/Type==10 KB (1,383 words) - 16:39, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,022 words) - 12:31, 3 November 2023
- ...can be found at [[HAEM4:Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1]]. ==Cancer Category / Type==18 KB (2,546 words) - 14:17, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==15 KB (1,965 words) - 14:30, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,443 words) - 12:30, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,652 words) - 14:34, 13 December 2023
- ...liferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)]]. ==Cancer Category / Type==18 KB (2,549 words) - 14:33, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,487 words) - 16:24, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==17 KB (2,372 words) - 14:31, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,651 words) - 14:36, 13 December 2023
- {{DISPLAYTITLE:Indolent T-cell lymphoma of the gastrointestinal tract}} ...template on 2023-12-07. The original page can be found at [[HAEM4:Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract]].20 KB (2,747 words) - 14:28, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,953 words) - 12:32, 3 November 2023
- ...www.ncbi.nlm.nih.gov/pubmed/?term=30377088 30377088]] with permission from Cancer Genetics. ''See [[MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alteration ==General Disease Overview / Description of Cancer Category==6 KB (789 words) - 16:21, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,578 words) - 12:33, 3 November 2023
- ...www.ncbi.nlm.nih.gov/pubmed/?term=30377088 30377088]] with permission from Cancer Genetics. ''See [[MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alteration ==General Disease Overview / Description of Cancer Category==6 KB (793 words) - 12:27, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,424 words) - 12:57, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,651 words) - 14:40, 13 December 2023
- {{DISPLAYTITLE:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder}} ==Cancer Category / Type==15 KB (2,180 words) - 16:34, 16 May 2024
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==17 KB (2,307 words) - 14:16, 13 December 2023
- ==Cancer Category / Type== * [[HAEM4:Mature T- and NK-cell Neoplasms]]19 KB (2,622 words) - 14:21, 13 December 2023
- {{DISPLAYTITLE:Monomorphic epitheliotropic intestinal T-cell lymphoma}} ...iginal page can be found at [[HAEM4:Monomorphic Epitheliotropic Intestinal T-cell Lymphoma]].19 KB (2,721 words) - 14:32, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,772 words) - 12:52, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,320 words) - 12:39, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==20 KB (2,830 words) - 14:34, 13 December 2023
- ...blastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)}} ==Cancer Category/Type==17 KB (2,470 words) - 14:00, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,772 words) - 13:44, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,723 words) - 12:45, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==15 KB (2,058 words) - 12:31, 3 November 2023
- ==Cancer Category/Type== *T-cell acute lymphoblastic leukaemia (T-ALL)14 KB (1,939 words) - 18:10, 5 January 2019
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,875 words) - 12:33, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,811 words) - 13:58, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==15 KB (2,015 words) - 14:30, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,762 words) - 13:54, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==10 KB (1,380 words) - 16:33, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,353 words) - 12:42, 3 November 2023
- {{DISPLAYTITLE:Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1}} ==Cancer Category/Type==20 KB (2,960 words) - 13:44, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,350 words) - 13:52, 25 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==22 KB (3,044 words) - 12:46, 3 November 2023
- {{DISPLAYTITLE:Hepatosplenic T-cell lymphoma}} ...ate on 2023-12-07. The original page can be found at [[HAEM4:Hepatosplenic T-cell Lymphoma]].19 KB (2,687 words) - 01:03, 12 May 2024
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,722 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,669 words) - 12:40, 3 November 2023
- {{DISPLAYTITLE:Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM}} [[File:t(3;3)(q21;q26.2).png|t(3;3)(q21;q26.2)]]17 KB (2,512 words) - 13:45, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,397 words) - 16:35, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==23 KB (3,086 words) - 16:38, 4 December 2023
- ...he original page can be found at [[HAEM4:Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3]]. ==Cancer Category / Type==21 KB (2,953 words) - 14:17, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==15 KB (2,067 words) - 14:23, 13 December 2023
- Victorian Cancer Cytogenetics Service ==Cancer Category/Type==18 KB (2,595 words) - 12:29, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,639 words) - 14:38, 13 December 2023
- ==Cancer Category/Type== *Mature T- and NK-cell Neoplasms12 KB (1,668 words) - 12:50, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (2,056 words) - 13:43, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,711 words) - 16:34, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (2,984 words) - 14:40, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,881 words) - 12:33, 3 November 2023
- Victorian Cancer Cytogenetics Service ==Cancer Category/Type==19 KB (2,643 words) - 16:23, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,921 words) - 12:29, 3 November 2023
- ==Cancer Category== *[[Mature T- and NK-cell Neoplasms|Mature T- and NK-cell Neoplasm]]12 KB (1,663 words) - 12:47, 3 November 2023
- ==Cancer Category/Type== *Mature T- and NK-cell Neoplasms13 KB (1,721 words) - 16:40, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,946 words) - 16:28, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,392 words) - 12:42, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==25 KB (3,405 words) - 14:26, 13 December 2023
- {{DISPLAYTITLE:Mixed-phenotype acute leukaemia, T/myeloid}} ...iginal page can be found at [[HAEM4:Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified]].19 KB (2,751 words) - 14:31, 13 December 2023
- {{DISPLAYTITLE:T-cell Large Granular Lymphocytic Leukemia}} ==Cancer Category==12 KB (1,707 words) - 16:38, 4 December 2023
- ==Cancer Category/Type== Mature T- and NK-Cell Neoplasms21 KB (3,034 words) - 12:48, 3 November 2023
- UT MD Anderson Cancer Center ==Cancer Category / Type==21 KB (2,945 words) - 14:37, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,486 words) - 12:44, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,440 words) - 16:35, 4 December 2023
- ...al page can be found at [[HAEM4:Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1]]. ==Cancer Category / Type==21 KB (2,942 words) - 14:31, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==14 KB (1,967 words) - 16:23, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,703 words) - 14:31, 13 December 2023
- {{DISPLAYTITLE:Adult T-cell Leukemia/Lymphoma}} ==Cancer Category/Type==22 KB (3,073 words) - 13:56, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==9 KB (1,330 words) - 12:36, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,920 words) - 14:35, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (2,882 words) - 12:37, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,531 words) - 16:36, 4 December 2023
- ...able derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics. All percentages are approximate. |t(12;21)(p13;q22); [[ETV6]]-[[RUNX1]]*33 KB (4,848 words) - 10:50, 26 July 2021
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,114 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,576 words) - 13:45, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==15 KB (2,091 words) - 13:44, 3 November 2023
- {{DISPLAYTITLE:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell ==Cancer Category / Type==23 KB (3,154 words) - 14:37, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (2,915 words) - 13:48, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,849 words) - 12:27, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==12 KB (1,693 words) - 12:30, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==24 KB (3,252 words) - 14:20, 13 December 2023
- {{DISPLAYTITLE:Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified}} ==Cancer Category/Type==10 KB (1,371 words) - 13:48, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,077 words) - 14:26, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,910 words) - 16:27, 4 December 2023
- ==Cancer Category/Type== * Angioimmunoblastic T-cell lymphoma20 KB (2,671 words) - 14:44, 10 August 2018
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,643 words) - 13:51, 25 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,890 words) - 13:40, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,362 words) - 12:53, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==13 KB (1,734 words) - 13:42, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,981 words) - 14:18, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,896 words) - 13:45, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==20 KB (2,857 words) - 14:35, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,865 words) - 12:30, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==19 KB (2,638 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,401 words) - 13:58, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,208 words) - 12:30, 3 November 2023
- ==Cancer Category / Type== Mature T- and NK-cell neoplasms21 KB (2,919 words) - 14:19, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (2,908 words) - 16:24, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==31 KB (4,428 words) - 12:28, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,250 words) - 16:24, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==32 KB (4,469 words) - 13:41, 3 November 2023
- {{DISPLAYTITLE:T-large granular lymphocytic leukaemia}} ...the new template on 2023-12-07. The original page can be found at [[HAEM4:T-cell Large Granular Lymphocytic Leukemia]].22 KB (3,037 words) - 14:41, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,506 words) - 12:47, 3 November 2023
- ==Cancer Category/Type== ...scular endothelial growth factor (''VEGF'') (Merdzhanova et al., 2010). In cancer, ''SRSF2'' variants have been implicated in leukemia and myeloid disorders16 KB (2,281 words) - 14:50, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,329 words) - 12:35, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==23 KB (3,226 words) - 12:31, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,152 words) - 14:16, 13 December 2023
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,285 words) - 15:49, 13 September 2019
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,285 words) - 16:56, 8 August 2020
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,029 words) - 12:39, 3 November 2023
- ==Cancer Category/Type== *[[Mature T- and NK-cell Neoplasms]]23 KB (3,346 words) - 12:52, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,549 words) - 16:38, 4 December 2023
- .... Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics. !Relevant Genes (if known)23 KB (3,282 words) - 11:49, 14 June 2019
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,890 words) - 14:33, 13 December 2023
- ...he original page can be found at [[HAEM4:Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]]. ==Cancer Category / Type==29 KB (4,172 words) - 14:17, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,428 words) - 12:27, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,369 words) - 13:47, 3 November 2023
- ==Cancer Category/Type== Breast Cancer / Epithelial Tumours of the Breast19 KB (2,737 words) - 13:17, 29 February 2024
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,639 words) - 14:37, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,967 words) - 14:22, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,072 words) - 16:33, 4 December 2023
- ==Cancer Category/Type== *[[HAEM4:Mature T- and NK-cell Neoplasms]]24 KB (3,388 words) - 16:41, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==21 KB (2,936 words) - 14:33, 13 December 2023
- ==Cancer Category/Type== Mature T- and NK-cell neoplasms10 KB (1,374 words) - 12:48, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,466 words) - 16:21, 4 December 2023
- ==Cancer Category/Type== *[[Mature T- and NK-cell Neoplasms]]22 KB (3,066 words) - 12:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,487 words) - 12:28, 3 November 2023
- ...e found at [[HAEM4:Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM]]. [[File:t(3;3)(q21;q26.2).png|t(3;3)(q21;q26.2)]]25 KB (3,672 words) - 14:17, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,522 words) - 12:33, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,528 words) - 13:41, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,647 words) - 12:46, 3 November 2023
- {{DISPLAYTITLE:Enteropathy-Associated T-cell Lymphoma}} ==Cancer Category/Type==22 KB (3,108 words) - 16:39, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==16 KB (2,213 words) - 12:30, 3 November 2023
- ==Cancer Category/Type== Mature T- and NK-cell neoplasms10 KB (1,411 words) - 16:38, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,561 words) - 16:27, 4 December 2023
- Victorian Cancer Cytogenetics Service ==Cancer Category / Type==28 KB (3,984 words) - 14:32, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,785 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==20 KB (2,685 words) - 16:37, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==24 KB (3,323 words) - 14:33, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,537 words) - 12:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==16 KB (2,255 words) - 13:42, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,643 words) - 14:36, 13 December 2023
- ==Cancer Category/Type== ...ET2 and WT1 physically interact, suggesting overlapping pathways for these genes in AML (Wang et al., 2015). ''TET2'' mutations increase the response of low26 KB (3,824 words) - 15:01, 12 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==23 KB (3,259 words) - 13:43, 3 November 2023
- {{DISPLAYTITLE:Adult T-cell leukaemia/lymphoma}} ...ew template on 2023-12-07. The original page can be found at [[HAEM4:Adult T-cell Leukemia/Lymphoma]].30 KB (4,300 words) - 14:18, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,527 words) - 14:25, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,586 words) - 16:35, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==24 KB (3,361 words) - 14:22, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==24 KB (3,361 words) - 14:22, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,046 words) - 12:33, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==30 KB (4,118 words) - 14:20, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==24 KB (3,384 words) - 12:52, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (3,028 words) - 12:27, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,680 words) - 14:26, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (3,055 words) - 13:40, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,330 words) - 12:30, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==24 KB (3,423 words) - 16:42, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==28 KB (3,914 words) - 14:36, 13 December 2023
- ...ed from Kanagal-Shawanna et al., 2018 [PMID 30377088] with permission from Cancer Genetics. ...urvival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J 2013;3:e155.[https://www.ncbi.nlm.nih.gov/pubmed/24185502]</ref><ref name38 KB (5,270 words) - 17:10, 30 April 2020
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==29 KB (4,102 words) - 14:17, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==27 KB (3,873 words) - 12:32, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,074 words) - 13:28, 29 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,371 words) - 13:42, 3 November 2023
- Patricia T. Greipp. D.O. ==General Disease Overview / Description of Cancer Category==7 KB (1,048 words) - 12:35, 3 November 2023
- Patricia T. Greipp. D.O. ==General Disease Overview / Description of Cancer Category==7 KB (1,048 words) - 16:29, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==32 KB (4,341 words) - 14:40, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==40 KB (5,552 words) - 14:34, 13 December 2023
- ==Cancer Category/Type== ===Role in Cancer===20 KB (2,904 words) - 03:02, 13 August 2018
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,703 words) - 14:23, 13 December 2023
- Cancer Metastasis Rev (2014) 33:1109–1124 PMID:[http://www.ncbi.nlm.nih.gov/pubm ...gnature PI3K/AKT and mTOR pathways elevated; high expression of several genes representing targets for immunotherapy including PDCD1, CD247, PDCD1LG2, CT8 KB (1,050 words) - 16:48, 19 August 2016
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,637 words) - 14:21, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==25 KB (3,458 words) - 14:35, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==22 KB (3,137 words) - 10:13, 27 February 2024
- !Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence ...linelibrary.wiley.com/doi/10.1002/gcc.22083|journal=Genes, Chromosomes and Cancer|language=en|volume=52|issue=10|pages=873–886|doi=10.1002/gcc.22083|issn=121 KB (3,051 words) - 17:48, 2 May 2024
- ...Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. |'''Genes'''17 KB (2,298 words) - 16:42, 22 April 2021
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==26 KB (3,699 words) - 14:26, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,670 words) - 12:38, 3 November 2023
- {{DISPLAYTITLE:Systemic EBV-positive T-cell lymphoma of childhood}} ...023-12-07. The original page can be found at [[HAEM4:Systemic EBV-Positive T-cell Lymphoma of Childhood]].26 KB (3,630 words) - 14:40, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==22 KB (3,071 words) - 13:45, 3 November 2023
- ==Cancer Category / Type== *[[HAEM4:Mature T- and NK-cell Neoplasms]]32 KB (4,584 words) - 14:16, 13 December 2023
- {{DISPLAYTITLE:Enteropathy-associated T-cell lymphoma}} ...23-12-07. The original page can be found at [[HAEM4:Enteropathy-Associated T-cell Lymphoma]].31 KB (4,371 words) - 14:25, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==29 KB (4,258 words) - 14:22, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==21 KB (2,978 words) - 13:33, 25 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==17 KB (2,410 words) - 12:42, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==29 KB (3,951 words) - 14:37, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==34 KB (4,742 words) - 14:34, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,828 words) - 14:18, 13 December 2023
- ==Cancer Category/Type== * [[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]24 KB (3,487 words) - 12:51, 3 November 2023
- ...n 2023-12-07. The original page can be found at [[HAEM4:Angioimmunoblastic T-cell Lymphoma]]. ==Cancer Category / Type==34 KB (4,909 words) - 14:35, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,476 words) - 16:34, 4 December 2023
- {{DISPLAYTITLE:Angioimmunoblastic T-cell Lymphoma}} ==Cancer Category/Type==24 KB (3,527 words) - 16:41, 4 December 2023
- ==Cancer Category/Type== ...a.io/index.php/T-Lymphoblastic_Leukemia/Lymphoma T-Lymphoblastic Leukemia (T-ALL)]20 KB (2,766 words) - 12:38, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,522 words) - 12:43, 3 November 2023
- {{DISPLAYTITLE:Early T-Cell Precursor Lymphoblastic Leukemia}} ==Cancer Category/Type==20 KB (2,803 words) - 16:32, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==34 KB (4,782 words) - 16:37, 20 December 2023
- ==Cancer Category/Type== [[HAEM4:Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]22 KB (3,117 words) - 15:04, 12 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==27 KB (3,735 words) - 14:32, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==18 KB (2,561 words) - 16:36, 4 December 2023
- {{DISPLAYTITLE:Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11}} ==Cancer Category/Type==27 KB (3,880 words) - 13:44, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==31 KB (4,299 words) - 14:17, 13 December 2023
- ==Cancer Category/Type== [[HAEM4:Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]24 KB (3,522 words) - 15:04, 12 December 2023
- ...L. Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics.'' See [[AML Table: Recurrent Genomic Alterations Detected by Chro ==General Disease Overview Description of Cancer Category==12 KB (1,714 words) - 16:25, 4 December 2023
- ...be found at [[HAEM4:Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]]. ==Cancer Category / Type==30 KB (4,324 words) - 14:16, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==24 KB (3,493 words) - 12:46, 3 November 2023
- ...L. Table derived from Xu et al., 2018 [PMID 30344013] with permission from Cancer Genetics.'' See [[AML Table: Recurrent Genomic Alterations Detected by Chro ==General Disease Overview Description of Cancer Category==12 KB (1,728 words) - 12:31, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==19 KB (2,686 words) - 13:49, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==23 KB (3,102 words) - 13:55, 25 February 2024
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==28 KB (3,970 words) - 14:19, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==24 KB (3,499 words) - 16:37, 4 December 2023
- {{DISPLAYTITLE:Early T-precursor lymphoblastic leukaemia / lymphoma}} ...ew template on 2023-12-07. The original page can be found at [[HAEM4:Early T-Cell Precursor Lymphoblastic Leukemia]].25 KB (3,503 words) - 14:24, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==33 KB (4,726 words) - 14:22, 13 December 2023
- ==Cancer Category/Type== *[[Mature T- and NK-cell Neoplasms]]33 KB (4,667 words) - 12:50, 3 November 2023
- ==Cancer Category/Type== *[[HAEM4:Mature T- and NK-cell Neoplasms]]33 KB (4,705 words) - 16:40, 4 December 2023
- ...somal abnormalities identified by standard methods has led to discovery of genes, and gene function and dysfunction. This knowledge has led to improved ther ..., et al.; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult59 KB (8,449 words) - 19:11, 27 July 2016
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==30 KB (4,394 words) - 12:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==31 KB (4,435 words) - 16:35, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==40 KB (5,557 words) - 12:42, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==40 KB (5,593 words) - 16:34, 4 December 2023
- ==Cancer Category / Type== *[[HAEM4:Mature T- and NK-cell Neoplasms]]42 KB (5,916 words) - 14:32, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==47 KB (6,652 words) - 12:47, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==40 KB (5,683 words) - 14:36, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification/Subtype==47 KB (6,699 words) - 16:38, 4 December 2023
- ==Cancer Category/Type== * Prostate cancer38 KB (5,062 words) - 12:33, 10 August 2018
- ...Table derived from Chun et al., 2018 [PMID 30554732] with permission from Cancer Genetics. |'''Relevant Genes'''40 KB (5,707 words) - 22:25, 7 November 2020
- ==Cancer Category/Type== *[[Mature T- and NK-cell Neoplasms]]16 KB (2,241 words) - 12:48, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==30 KB (4,094 words) - 12:53, 3 November 2023
- {{DISPLAYTITLE:Systemic EBV-Positive T-cell Lymphoma of Childhood}} ==Cancer Category/Type==16 KB (2,284 words) - 16:39, 4 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==34 KB (4,834 words) - 14:25, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==31 KB (4,295 words) - 14:22, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==31 KB (4,151 words) - 16:42, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==33 KB (4,821 words) - 12:54, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==39 KB (5,484 words) - 14:43, 20 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==48 KB (6,794 words) - 14:27, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==46 KB (6,456 words) - 12:45, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==33 KB (4,858 words) - 13:58, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==46 KB (6,495 words) - 13:54, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==56 KB (7,988 words) - 14:24, 13 December 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category / Type==41 KB (5,923 words) - 14:31, 13 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==42 KB (6,120 words) - 14:27, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,599 words) - 12:27, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==25 KB (3,637 words) - 13:40, 3 November 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category/Type==32 KB (4,668 words) - 12:44, 3 November 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==50 KB (7,282 words) - 12:44, 3 November 2023
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category/Type==32 KB (4,712 words) - 16:36, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==51 KB (7,325 words) - 16:36, 4 December 2023
- ==Cancer Category/Type== '''Natural Killer/T-cell Lymphoma'''36 KB (5,335 words) - 14:18, 12 December 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==55 KB (7,745 words) - 14:29, 13 December 2023
- ..., MS, Neuropathology Fellow Houston Methodist/Texas Children’s/MD Anderson Cancer Center ==Cancer Category/Type==36 KB (5,058 words) - 13:49, 25 February 2024
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==35 KB (4,909 words) - 12:40, 3 November 2023
- ==Cancer Category / Type== ==Cancer Sub-Classification / Subtype==52 KB (7,572 words) - 14:28, 13 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==35 KB (4,949 words) - 16:33, 4 December 2023
- ==Cancer Category/Type== *[[Mature T- and NK-cell Neoplasms]]54 KB (7,733 words) - 12:52, 3 November 2023
- ==Cancer Category/Type== *[[HAEM4:Mature T- and NK-cell Neoplasms]]55 KB (7,774 words) - 16:41, 4 December 2023
- ==Cancer Category/Type== ==Cancer Sub-Classification / Subtype==31 KB (4,325 words) - 13:55, 25 February 2024
- ::T-cell and NK/T-cell lymphomas ::Mismatch repair cancer syndrome38 KB (3,868 words) - 13:56, 12 December 2023
- ==Cancer Category / Type== *[[HAEM4:Mature T- and NK-cell Neoplasms]]64 KB (9,095 words) - 14:16, 13 December 2023
- ...Table derived from Liu et al., 2020 [PMID 32434132] with permission from Cancer Genetics. ...ehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer|url=https://pubmed.ncbi.nlm.nih.gov/23083876|journal=The Journal of Urology42 KB (5,820 words) - 13:40, 19 May 2021
- |Gokce A. Toruner, MD, PhD UT MD Anderson Cancer Center |T. Niroshi Senaratne, UCLA61 KB (7,864 words) - 16:23, 16 April 2024
- ...ist is based on the 2016 [http://cancer.sanger.ac.uk/census/ Sanger Centre Cancer Gene Census]. | [[ABL1]] || 9q34.1 || [[CML]],[[ALL]],[[T-ALL]] || [[BCR]],[[ETV6]],[[NUP214]]38 KB (4,038 words) - 18:34, 17 July 2016
- The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas ==Cancer Category / Type==80 KB (11,414 words) - 14:36, 13 December 2023
- ...oing to be much better for clinical and pathologic information, and we don't want to reproduce that work here. Hopefully, this will help reduce your wo The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas73 KB (10,415 words) - 12:41, 3 November 2023
- ...oing to be much better for clinical and pathologic information, and we don't want to reproduce that work here. Hopefully, this will help reduce your wo The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas73 KB (10,453 words) - 13:51, 3 November 2023
- ...://pubmed.ncbi.nlm.nih.gov/32203924/ PMID: 32203924]] with permission from Cancer Genetics. ...ilocytic astrocytomas|url=https://pubmed.ncbi.nlm.nih.gov/18974108|journal=Cancer Research|volume=68|issue=21|pages=8673–8677|doi=10.1158/0008-5472.CAN-08-103 KB (13,991 words) - 17:05, 20 April 2021